APA (7th ed.) Citation

S, S., CD, E., M, L., SW, A., MJ, P., BA, W., . . . JR, S. (2022). Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA neurology, 79(10), 1015. https://doi.org/10.1001/jamaneurol.2022.2793

Chicago Style (17th ed.) Citation

S, Shcherbinin, et al. "Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial." JAMA Neurology 79, no. 10 (2022): 1015. https://doi.org/10.1001/jamaneurol.2022.2793.

MLA (9th ed.) Citation

S, Shcherbinin, et al. "Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial." JAMA Neurology, vol. 79, no. 10, 2022, p. 1015, https://doi.org/10.1001/jamaneurol.2022.2793.